On June 29, 2026, one of the most consequential hearings in the history of US cannabis policy, the crucial DEA Administrative Law Judge (ALJ) hearing that could determine whether adult-use cannabis joins state-licensed medical cannabis on Schedule III of the Controlled Substances Act, begins proceedings.
The UK’s health service is fighting to keep its head above water, yet with a record-breaking winter flu pandemic sweeping the nation, and a looming industrial action set to see thousands of resident doctors walk out later this week, the water level is rising rapidly.
Why Reading Research Matters The volume of cannabis research has never been higher, but not all studies are created equal.
First published on Cannabis Health Medical cannabis patients made history in London with a first-of-its-kind, patient-led education event focused on cannabis-based medicines, hosted at the Charterhouse.
Sorting Evidence from Anecdote As global cannabis research accelerates, the number of published studies has never been higher, but not all evidence carries the same scientific weight.
Accredited Medical Cannabis Symposium Could ‘Benefit Thousands of Patients’, Says Expert
The European medical cannabis industry is continuing to mature, seeing companies focused on science-based research push the boundaries of our understanding of its use cases, and more importantly, fill the long-maligned gap in clinical evidence.
Since Germany’s Cannabis Act (CanG) came into force on 1 April 2024, much has changed regarding what was once the country’s most widely used illegal drug.
When Germany introduced the Recreational Cannabis Act (KCanG), it not only legalised home cultivation and consumption for adults but also laid the groundwork for scientifically monitored pilot projects allowing the legal sale of cannabis at authorised distribution points.
